Nasdaq Halts Biotech Merger, Citing Financial and Operational Weakness

STOCKHOLM, Sweden – February 24, 2026 – A strategic plan to bring a promising vaccine developer to the public market has been abruptly terminated after regulators at Nasdaq Stockholm rejected the proposed deal. The planned reverse acquisition of SVF Vaccines by the publicly listed Novakand Pharma will not proceed, a major setback for SVF’s ambitious clinical development plans and its lead investor, KDventures AB.

In a statement released today, KDventures, which holds a 33 percent stake in SVF Vaccines, confirmed the collapse of the transaction. The deal's completion was contingent on the combined company securing approval for continued listing on the Nasdaq First North Growth Market. That approval was denied.

According to the announcement, Nasdaq determined that the application failed to demonstrate that the merged entity would meet the exchange's requirements for “active operations or sufficient working capital.” The decision effectively scuttles the merger announced just weeks earlier on February 6, 2026, forcing SVF Vaccines and KDventures to reassess their strategy for funding future growth.

A Regulatory Red Flag on Financial Viability

Nasdaq’s rejection shines a spotlight on the stringent gatekeeping role exchanges play, particularly concerning reverse mergers in the capital-intensive biotech sector. The decision was not made in a vacuum but appears rooted in the precarious financial and operational standing of the acquiring company, Novakand Pharma AB.

Novakand, which rebranded from Kancera AB in September 2025, has been under regulatory scrutiny for months. In November 2025, Nasdaq placed the company’s shares under “observation status.” This move was triggered by a critical decision in its third-quarter report to write down the value of its entire fractalkine drug program to zero—a significant blow to its asset base and future prospects. Financial reports from 2025 painted a stark picture, with the company reporting zero net sales in consecutive quarters and declining research and development expenditures.

For Nasdaq, the proposed merger would have constituted a substantial change for Novakand, prompting a full relisting review. Regulators ultimately concluded that the company, even when combined with SVF Vaccines' assets, did not demonstrate a sufficiently robust operational or financial foundation to warrant a public listing. The lack of revenue-generating activities and a deteriorating balance sheet at Novakand likely served as insurmountable hurdles, leading to Nasdaq’s assessment that the combined entity lacked the necessary substance to protect public market investors.

This case serves as a cautionary tale for the life sciences industry, where reverse takeovers are often viewed as a faster, more efficient path to public markets than a traditional IPO. It underscores that regulators are increasingly vigilant in ensuring that such transactions are not merely vehicles for struggling public shells to absorb private assets without the underlying financial strength to support long-term development.

A Setback for a Promising Vaccine Pipeline

The collapse of the merger is a particularly significant blow given the promise held within SVF Vaccines' pipeline. The company, a spin-out from the prestigious Karolinska Institute, is focused on developing next-generation immunotherapies for major global health challenges. The public listing via Novakand was intended to provide the capital necessary to accelerate its clinical trials.

At the forefront of its portfolio is SVF-001, a therapeutic vaccine for chronic hepatitis B (HBV) and hepatitis D (HDV). This program is currently preparing to enter Phase 1 clinical studies. The unmet medical need is immense; over 250 million people suffer from chronic HBV, and an estimated 12 million of them are co-infected with HDV, the most severe form of viral hepatitis. These infections are responsible for approximately 800,000 deaths annually from complications like liver failure and cancer. While a prophylactic vaccine for HBV exists, there are no curative treatments for those already chronically infected. Current therapies are lifelong and often have limited efficacy, making SVF-001 a potentially transformative product in a multi-billion dollar market.

Beyond hepatitis, SVF Vaccines has also developed SVF-002, a universal COVID-19 vaccine candidate. This DNA-based vaccine successfully completed a Phase 1 study in 2024, demonstrating positive safety and immunogenicity data. It is designed to elicit a broad immune response, including T-cells that can eliminate infected cells, making it a potential tool against future coronavirus variants.

Without the anticipated influx of capital from the public markets, the timeline for advancing these critical programs is now uncertain.

KDventures Faces a Strategic Pivot

For investment firm KDventures, the failed merger forces a strategic pivot. As the owner of a 33 percent stake, the reverse takeover represented a clear path toward realizing value from one of its key portfolio assets while ensuring its continued development. The firm’s model relies on identifying early-stage Nordic life science innovations and guiding them toward commercialization, and this public listing was a crucial step in that process for SVF Vaccines.

The setback comes at a challenging time for KDventures, which saw its net asset value decline in 2025. The firm now faces the task of finding a new way to secure the substantial funding SVF Vaccines requires for its clinical journey. In its official statement, KDventures CEO Viktor Drvota confirmed the company is now “evaluating alternative paths forward in order to best realize SVF Vaccines' continued development plans.”

Those alternative paths will be critical. The high-potential science behind SVF Vaccines remains unchanged, making it an attractive asset despite the failed transaction. The company could pursue a significant private funding round from venture capital or private equity firms specializing in biotech. Another strong possibility is a strategic partnership or licensing deal with a large pharmaceutical company. Many major pharma players are flush with cash and actively seeking to fill their pipelines with innovative assets, particularly in high-need areas like infectious diseases. An outright acquisition by a more financially stable company also remains a viable option.

The road ahead for SVF Vaccines has become more complex, but the inherent value of its scientific platform provides a strong foundation for its next chapter.